Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Vis graf over relationer


In vivo evaluation of novel positron emission tomography (PET) radioligands for different targets (proteins or enzymes) in the pig brain; PET-MR imaging of non-human primates; PET-MR imaging of healthy subjects; Good clinical practise (GCP) experience with regards to PET-MR imaging in humans; Project management of various pre-clinicial and clinical projects; Supervision of master and PhD students.

Primære forskningsområder

PET-MR imaging; radioligand development; pre-clinical imaging, clinical imaging, pharmacology

Aktuel forskning

Cerebral pharmacodynamic effects of 5-HT1B receptor stimulation - A translational study: With PET-MR imaging I'm investigating the effects of different drugs targeting the serotonin 1B (5-HT1B) receptor in the brain. This is a proof-of-concept that PET-MR imaging can be used to identify the functionality of these drugs (i.e. whether they are agonist or antagonists), blood brain barrier penetration and target involvement.

Radioligand development: At NRU we continue to develop new PET radioligands mainly for the serotonin system. We have develop radioligands for the 5-HT2A receptor and the 5-HT7 receptor.

Epigenentics and PET: With a novel radioligand targeting the histone deacetylase (HDAC) enzymes we will investigate what effect different pharmacological interventions has on the epigenetic machinery in pigs. This project has the potential to find epigenetic changes in vivo (using PET imaging) and correlate these findings with downstream mechanism, which we will identify with various in vitro methods.

Mulige interessekonflikter

No potential conflict of interest

ID: 41459031